Product Description
INBRX-130 is a CONTRA-MAB® that targets trophoblast glycoprotein (TPBG; 5T4), a cell-surface protein that is upregulated across many solid tumor indications but has restricted expression on normal adult tissues. As determined by flow cytometry, INBRX-130 exhibits specific and high-affinity binding to 5T4-positive cells but shows no detectable binding to T cells, absent target, at concentrations up to one micromolar. Additionally, treatment of peripheral blood mononuclear cells (PBMCs) with high concentration INBRX-130 does not result in production of detectable levels of CRS-associated inflammatory cytokines. (Sourced from: https://aacrjournals.org/cancerres/article/82/12_Supplement/2912/700371/Abstract-2912-INBRX-130-a-5T4-targeted-CONTRA-MAB)
Mechanisms of Action: TPBG Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inhibrx
Company Location: LA JOLLA CA 92037
Company CEO: Mark P. Lappe
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|